Hybrid Convergent ablation for atrial fibrillation: A systematic review and meta-analysis

Shrestha, Suvash; Plasseraud, Kristen M; Makati, Kevin J.; Sood, Nitesh; Killu, Ammar M.; Contractor, Tahmeed; Ahsan, Syed; Lurgio, David B. De; Shults, Christian; Eldadah, Zayd; Russo, Andrea M.; Knight, Bradley P.; Greenberg, Yisachar; Yang, Felix

doi:10.1016/j.hroo.2022.05.006

Cited by 15 publications

(18 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29 The benefit of hybrid ablation over catheter ablation alone is further documented by several meta-analyses. [30][31][32] Given these data, we should anticipate increased uptake among surgeons in the coming years.…”

Section: Tale Of Two Trials In Support Of Hybrid Ablation For Persist...mentioning

confidence: 99%

Noteworthy in Cardiothoracic Surgery 2023

Rove,

Cain,

Hoffman

et al. 2024

Semin Cardiothorac Vasc Anesth

View full text Add to dashboard Cite

Noteworthy in Cardiothoracic Surgery 2023 summarizes a few of the most high-impact trials and provocative trends in cardiothoracic surgery and transplantation this past year. Transplantation using organs procured from donation after circulatory death (DCD) continues to increase, and the American Society of Transplant Surgeons released recommendations on best practices in 2023. We review a summary of data on the impact of DCD on heart and lung transplantation. There has been increased interest in extracorporeal life support (ECLS), particularly after the COVID-19 pandemic, and we review the results of the highly discussed ECLS-SHOCK trial, which randomized patients in cardiogenic shock with planned revascularization to ECLS vs usual care. With improving survival outcomes in complex aortic surgery, there is a need for higher-quality evidence to guide which cooling and cerebral perfusion strategies may optimize cognitive outcomes in these patients. We review the short-term outcomes of the GOT ICE trial (Cognitive Effects of Body Temperature During Hypothermic Circulatory Arrest), a multicenter, randomized controlled trial of three different nadir temperatures, evaluating outcomes in cognition and associated changes in functional magnetic resonance imaging. Finally, both the Society of Thoracic Surgeons (STS) and the American College of Cardiology, American Heart Association, American College of Chest Physicians and Heart Rhythm Society (ACC/AHA/ACCP/HRS) updated atrial fibrillation guidelines in 2023, and we review surgically relevant updates to the guidelines and the evidence behind them.

show abstract

Section: Tale Of Two Trials In Support Of Hybrid Ablation For Persist...mentioning

confidence: 99%

Noteworthy in Cardiothoracic Surgery 2023

Rove,

Cain,

Hoffman

et al. 2024

Semin Cardiothorac Vasc Anesth

View full text Add to dashboard Cite

show abstract

“…Several single center studies have been published describing the midterm outcomes of the Hybrid Convergent procedure. 19,20 The CONVERGE clinical trial, a multicenter randomized controlled trial that evaluated the safety of the Hybrid Convergent combined ablation treatment and its effectiveness versus standard endocardial ablation in the persistent and long-standing persistent AF patients.…”

Section: Hybrid Ablationmentioning

confidence: 99%

“…With few comparative studies or studies exclusively looking at hybrid convergent ablation after previous catheter ablation patients, more research as well as additional cumulative real-world evidence is necessary to determine whether there are any significant differences in procedural and treatment outcomes. 19…”

Section: Prior Failed Catheter Ablationmentioning

confidence: 99%

“…Additionally, fewer patients who had prior ablation needed cardioversions (26.7%) to achieve sinus rhythm intraprocedurally compared to those receiving hybrid ablation as a first ablation procedure (45.8%, p = .038). With few comparative studies or studies exclusively looking at hybrid convergent ablation after previous catheter ablation patients, more research as well as additional cumulative real‐world evidence is necessary to determine whether there are any significant differences in procedural and treatment outcomes 19 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Selection of patients for hybrid ablation procedure

Lurgio

2023

Cardiovasc electrophysiol

Self Cite

View full text Add to dashboard Cite

Catheter ablation for treatment of symptomatic non‐paroxysmal atrial fibrillation remains challenging. Clinical failure and need for continued medical therapy or repeat ablation is common, especially in more advanced forms of atrial fibrillation. Hybrid ablation has emerged as a more effective and safe therapy than endocardial‐only ablation particularly for longstanding persistent atrial fibrillation as demonstrated by the randomized controlled CONVERGE trial. Hybrid ablation requires collaboration of electrophysiologists and cardiac surgeons to develop specific workflows. This review describes the Hybrid Convergent approach in the context of available ablation options and offers guidance for workflow development and patient selection.

show abstract

“…Several single center studies have been published describing the mid-term outcomes of the Hybrid Convergent procedure. 19,20 The CONVERGE clinical trial, a multicenter randomized controlled trial that evaluated the safety of the Hybrid Convergent combined ablation treatment and its effectiveness versus standard endocardial ablation in the persistent and long-standing persistent AF patients. Based on these results, the Hybrid Convergent procedure using the EPi-Sense device (AtriCure, Inc.) for epicardial ablation augmented by endocardial catheter ablation is the only FDA-approved minimally invasive treatment for longstanding persistent AF.…”

Section: Endocardial Ablationmentioning

confidence: 99%

Selection of Patients for Hybrid Ablation Procedure

Lurgio

2022

Preprint

View full text Add to dashboard Cite

Catheter ablation for treatment of symptomatic non-paroxysmal atrial fibrillation remains challenging. Clinical failure and need for continued medical therapy or repeat ablation is common, especially in more advanced forms of atrial fibrillation. Hybrid ablation has emerged as a more effective and safe therapy than endocardial-only ablation particularly for longstanding persistent atrial fibrillation as demonstrated by the randomized controlled CONVERGE trial. Hybrid ablation requires collaboration of electrophysiologists and cardiac surgeons to develop specific workflows. This review describes the Hybrid Convergent approach in the context of available ablation options and offers guidance for workflow development and patient selection.

show abstract

Hybrid Convergent ablation for atrial fibrillation: A systematic review and meta-analysis

Cited by 15 publications

References 29 publications

Noteworthy in Cardiothoracic Surgery 2023

Noteworthy in Cardiothoracic Surgery 2023

Selection of patients for hybrid ablation procedure

Selection of Patients for Hybrid Ablation Procedure

Contact Info

Product

Resources

About